Emerging therapies for relapsing multiple sclerosis

Archives of Neurology

Volumn 66, Issue 7, 2009, Pages 821-828

  Cohen, Jeffrey A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ATORVASTATIN; BETA1A INTERFERON; BHT 3008; CLADRIBINE; DACLIZUMAB; DIMETHYL FUMARIC ACID; DIRUCOTIDE; DNA VACCINE; ESTRIOL; FINGOLIMOD; FUMARIC ACID DERIVATIVE; GADOLINIUM; GLATIRAMER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON BETA SERINE; LAQUINIMOD; METHOTREXATE; MINOCYCLINE; MITOXANTRONE; NATALIZUMAB; NEUTRALIZING ANTIBODY; OCRELIZUMAB; PLACEBO; RITUXIMAB; SIMVASTATIN; SYNTHETIC PEPTIDE; TEMSIROLIMUS; TERIFLUNOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ADULT RESPIRATORY DISTRESS SYNDROME; ALOPECIA; ANAPHYLAXIS; ANTIBODY TITER; APHTHOUS STOMATITIS; ARTHRALGIA; AUTOIMMUNITY; B CELL LEUKEMIA; BLOOD PRESSURE; BONE MARROW SUPPRESSION; BRADYCARDIA; BUDD CHIARI SYNDROME; BURSITIS; CHRONIC LYMPHATIC LEUKEMIA; CONTRAST ENHANCEMENT; CYTOKINE RELEASE; CYTOKINE RELEASE SYNDROME; DEMYELINATING DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEVER; FLUSHING; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL SYMPTOM; GRAFT REJECTION; GRAVES DISEASE; HAIRY CELL LEUKEMIA; HEADACHE; HEART INFARCTION; HERPES; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFECTIOUS COMPLICATION; INJECTION SITE REACTION; KIDNEY ALLOGRAFT REJECTION; LEUKOPENIA; LIMB PAIN; LIVER NECROSIS; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MALAISE; MENSTRUATION DISORDER; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPPORTUNISTIC INFECTION; PANCREATITIS; PANCYTOPENIA; PERICARDITIS; PLEURA EFFUSION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; RASH; RELAPSE; REMISSION; RETINA MACULA EDEMA; REVIEW; RHABDOMYOLYSIS; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; RIGOR; SIDE EFFECT; SKIN MANIFESTATION; SYNDROME; SYNDROME DELINEATION; TACHYCARDIA; TERATOGENICITY; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT OUTCOME; URTICARIA; VASCULAR DISEASE; VOMITING;

CLINICAL TRIALS AS TOPIC; EMERGENCY TREATMENT; ENZYME INHIBITORS; ESTRIOL; HUMANS; IMMUNOLOGIC FACTORS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE;

EID: 67650481214     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.104     Document Type: Review

References (48)

1. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol. 1999;46(3):296-304.
2. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology. 1999;53(4):751-757.
3. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol. 2006;253(1):98-108.
4. CAMMS223 Trial Investigators; Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786-1801.
5. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691-1695.
6. ClinicalTrials.gov. http://clinicaltrials.gov. Accessed November 1, 2008.
7. Hafler DA, Compston A, Sawcer S, et al; International Multiple Sclerosis Genetics Consortium. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007;357(9):851-862.
8. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A. 2006;103(15):5941-5946.
9. Rose JW, Watt HE, White AT, Carlson NG. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol. 2004;56(6):864-867.
10. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β. Proc Natl Acad Sci U S A. 2004;101:8705-8708.
11. Kaufman MD, Wynn DR, Montalban X. A phase 2 randomized, double-blinded, placebo-controlled, multicenter study of subcutaneous daclizumab, a humanized, anti-CD-25 monoclonal antibody, in patients with active, relapsing forms of multiple sclerosis: week 44 results [abstract PL01.003]. Neurology. 2008;70(suppl 1):A220.
12. McFarland HF. The B cell: old player, new position on the team [editorial]. N Engl J Med. 2008;358(7):664-665.
13. Dalakas MC. Inhibition of B cell functions: implications for neurology. Neurology. 2008;70(23):2252-2260.
14. Hauser SL, Waubant E, Arnold DL, et al; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676-688.
15. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum. 2007;56(7):2116-2128.
16. Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol. 2006;13(8):887-895.
17. Bar-Or A, Vollmer T, Antel J, et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol. 2007;64(10):1407-1415.
18. Garren H, Robinson WH, Krasulova E, et al; BHT-3009 Study Group. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol. 2008;63(5):611-620.
19. Beutler E, Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996;93(4):1716-1720.
20. Brousil JA, Roberts RJ, Schlein AL. Cladribine: an investigational immunomodulatory agent for multiple sclerosis. Ann Pharmacother. 2006;40(10):1814-1821.
21. Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994;344(8914):9-13.
22. Rice GPA, Filippi M, Comi G; Cladribine MRI Study Group. Cladribine and progressive MS. clinical and MRI outcomes of a multicenter controlled trial. Neurology. 2000;54(5):1145-1155.
23. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol. 2005;58(6):840-846.
24. Lukashev M, Zeng W, Goetz S, et al. Activation of Nrf2 and modulation of disease progression in EAE models by BG00012 (dimethylfumarate) suggests a novel mechanism of action combining anti-inflammatory and neuroprotective modalities [abstract]. Mult Scler. 2007;13:A503.
25. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol. 2006;145(1):101-107.
26. Kappos L, Gold R, Miller DH, et al; BG-12 Phase IIb Study Investigators. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomized, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463-1472.
27. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T; Pregnancy in Multiple Sclerosis Group. Rate of pregnancy-related relapse in multiple sclerosis. N Engl J Med. 1998;339(5):285-291.
28. Gilmore W, Weiner LP, Correale J. Effect of estradiol on cytokine secretion by proteolipid protein-specific T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol. 1997;158(1):446-451.
29. Kim S, Liva S, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology. 1999;52(6):1230-1238.
30. Massberg S, Von Andrian UH. Fingolimod and sphingosine-1-phosphate - modifiers of lymphocyte migration. N Engl J Med. 2006;355(11):1088-1091.
31. Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: Implications for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117(1):77-93.
32. Kappos L, Antel J, Comi G, et al; FTY720 D2201 Study Group. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140.
33. Andersen O, Lycke J, Tollesson PO, et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 1996;47(4):895-900.
34. Noseworthy JH, Wolinsky JS, Lublin FD, et al; North American Linomide Investigators. Linomide in relapsing and secondary progressive MS, part I: trial design and clinical results. Neurology. 2000;54(9):1726-1733.
35. Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O, Nederman T; Laquinimod in RelapsingMSStudy Group. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology. 2005;64(6):987-991.
36. Comi G, Pulizzi A, Rovaris M, et al; LAQ/5062 Study Group. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;371(9630):2085-2092.
37. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol. 2004;3(12):744-751.
38. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis [letter]. Ann Neurol. 2004;55(5):756.
39. Metz L, Li D, Traboulsee A, et al. Glatiramer acetate combined with minocycline reduces the number of T1 Gd-enhancing and new T2 lesions compared to glatiramer alone [abstract S02.003]. Neurology. 2007;68(suppl 1):A84-A85.
40. Youssef S, Stuve O, Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420(6911):78-84.
41. Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators: comparison with interferon-β1b in MS. Neurology. 2002;59(7):990-997.
42. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE. 2008;3(4):e1928.
43. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet. 2004;363(9421):1607-1608.
44. Goldstein LB, Amarenco P, Szarek M, et al; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology. 2008;70(24, pt 2):2364-2370.
45. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390-1395.
46. Kieseier BC, Archelos JJ, Hartung HP. Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol. 2004;61(6):929-932.
47. Kappos L, Barkhof F, Desmet A, et al. The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis: results from a randomized controlled clinical trial [abstract 158]. J Neurol. 2005;252(suppl 2):46.
48. O'Connor PW, Li D, Freedman MS, et al; Teriflunomide Multiple Sclerosis Trial Group; University of British Columbia MS/MRI Research Group. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology. 2006;66(6):894-900.